Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio Iannitto

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
Cancer|September 25, 2004
Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patientsEmilio Iannitto, Achille Ambrosetti, Emanuele Ammatuna, et al.
Cancer|November 25, 2003
Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio LinfomiPaolo G Gobbi, Chiara Broglia, Francesco Merli, et al.
European Journal of Haematology|February 8, 2005
Hepatitis B virus reactivation and alemtuzumab therapyEmilio Iannitto, Viviana Minardi, Giuseppina Calvaruso, et al.
European Journal of Haematology|January 13, 2006
Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphomaEmilio Iannitto, Viviana Minardi, Vincenzo Callea, et al.
Cancer|September 17, 2004
The clinical value of tumor burden at diagnosis in Hodgkin lymphomaPaolo G Gobbi, Chiara Broglia, Giuseppe Di Giulio, et al.
Oncology Reports|March 17, 2009
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphomaPaolo G Gobbi, Francesco Valentino, Marco Danova, et al.
Mayo Clinic Proceedings|June 6, 2015
Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 PatientsTamar Tadmor, Alessia Bari, Luigi Marcheselli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumorsPaolo G Gobbi, Chiara Broglia, Alessandro Levis, et al.
Leukemia & Lymphoma|September 16, 2011
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trialFortunato Morabito, Stefan Hohaus, Corrado Mammi, et al.
Blood|June 22, 2007
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trialAndrea Gallamini, Francesco Zaja, Caterina Patti, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
Cancer|September 25, 2004
Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patientsEmilio Iannitto, Achille Ambrosetti, Emanuele Ammatuna, et al.
Cancer|November 25, 2003
Vinblastine, bleomycin, and methotrexate chemotherapy plus irradiation for patients with early-stage, favorable Hodgkin lymphoma: the experience of the Gruppo Italiano Studio LinfomiPaolo G Gobbi, Chiara Broglia, Francesco Merli, et al.
European Journal of Haematology|February 8, 2005
Hepatitis B virus reactivation and alemtuzumab therapyEmilio Iannitto, Viviana Minardi, Giuseppina Calvaruso, et al.
European Journal of Haematology|January 13, 2006
Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphomaEmilio Iannitto, Viviana Minardi, Vincenzo Callea, et al.
Cancer|September 17, 2004
The clinical value of tumor burden at diagnosis in Hodgkin lymphomaPaolo G Gobbi, Chiara Broglia, Giuseppe Di Giulio, et al.
Oncology Reports|March 17, 2009
Bone marrow stem cell damage after three different chemotherapy regimens for advanced Hodgkin's lymphomaPaolo G Gobbi, Francesco Valentino, Marco Danova, et al.
Mayo Clinic Proceedings|June 6, 2015
Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 PatientsTamar Tadmor, Alessia Bari, Luigi Marcheselli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2006
MOPPEBVCAD chemotherapy with limited and conditioned radiotherapy in advanced Hodgkin's lymphoma: 10-year results, late toxicity, and second tumorsPaolo G Gobbi, Chiara Broglia, Alessandro Levis, et al.
Leukemia & Lymphoma|September 16, 2011
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trialFortunato Morabito, Stefan Hohaus, Corrado Mammi, et al.
Blood|June 22, 2007
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trialAndrea Gallamini, Francesco Zaja, Caterina Patti, et al.
Pageof 7